Better Buy: Amwell vs. Teladoc
Like those who sell sunscreen at the beach or umbrellas on a rainy day, telehealth providers found themselves in demand this spring when the novel coronavirus shut down everyday life. As we've adapted to living with the virus, those virtual visits have dropped off, and investors are left wondering how much patient behavior will change permanently -- and which telehealth provider is in the best position to benefit.
Amwell (NYSE: AMWL) and Teladoc (NYSE: TDOC), along with privately held MDLive, are the primary players in the telehealth market. As virtual visits became the sole way for people not suffering from COVID-19 to see many clinicians, these services came to provide invaluable substitutes for routine office visits. But while the businesses seem very similar, there are some key differences. Examining them will help us understand which company will make a better investment over the next three to five years.
Image source: Getty Images.
Source Fool.com
